help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barkan, A. L.
Right arrow Articles by Beitins, I. Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barkan, A. L.
Right arrow Articles by Beitins, I. Z.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Journal of Clinical Endocrinology & Metabolism, Vol 66, 16-23, Copyright © 1988 by Endocrine Society


ARTICLES

Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995

AL Barkan, RP Kelch, NJ Hopwood and IZ Beitins
Department of Medicine, Veterans Administration Medical Center, Ann Arbor, Michigan 48105.

Current treatment of acromegaly (surgery, radiation, and bromocriptine) is often unsatisfactory, and a sizeable proportion of patients with this disease continue to have GH hypersecretion after all therapeutic modalities have been exhausted. Fifteen patients with active acromegaly (8 previously treated and 7 newly diagnosed) were treated with the long- acting somatostatin analog SMS 201-995 (Sandoz; 50-250 micrograms, sc, every 6-8 h for up to 21 months). The mean daily plasma GH concentration was significantly suppressed in 13 patients, and it became normal in 10. Two patients, however, did not have GH suppression by SMS 201-995 treatment alone; in 1, a significant decline in mean daily GH was achieved after the addition of bromocriptine. As expected, suppression of GH secretion was associated with normalization of plasma somatomedin-C values and significant clinical improvement. Plasma GH responses to synthetic GHRH-(1-44) and TRH were either abolished or blunted by SMS 201-995. Thyroid function remained normal, and glucose tolerance did not change. Significant shrinkage of pituitary tumors occurred in 7 previously untreated and 2 previously treated patients. Side-effects were minimal. SMS 201-995 is an effective agent for the treatment of acromegaly. Further studies are necessary to establish guidelines for identification of non-responders and to examine the effect of preoperative tumor shrinkage on subsequent surgical outcome.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
K. Bajuk Studen and A. Barkan
Assessment of the Magnitude of Growth Hormone Hypersecretion in Active Acromegaly: Reliability of Different Sampling Models
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 491 - 496.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. V. Dimaraki, W. F. Chandler, M. B. Brown, C. A. Jaffe, S. Y. Kim, R. Taussig, V. Padmanabhan, and A. L. Barkan
The Role of Endogenous Growth Hormone-Releasing Hormone in Acromegaly
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2185 - 2190.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. S. Bevan
The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1856 - 1863.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
I. Yang, S. Park, J. Woo, S. Kim, J. Kim, Y. Kim, and Y. Choi
Growth Hormone Response to the Hypothalamic Somatostatinergic Activity in Acromegalic Patients
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2492 - 2496.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. K. Flogstad, J. Halse, S. Bakke, I. Lancranjan, P. Marbach, Ch. Bruns, and J. Jervell
Sandostatin LAR in Acromegalic Patients: Long Term Treatment
J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 23 - 28.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society